Professor Karen Brown
Professor of Translational Cancer Research
- Tel: 0116 223 1851
- Email: firstname.lastname@example.org
- Office: CSMM, Level 5 Offices, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE1 5WW
- B.Pharm, University of Bradford
- MRPharmS, Royal Pharmaceutical Society of Great Britain
- PhD in Pharmaceutical Chemistry, University of Bradford
Preclinical and early clinical development of novel cancer chemopreventive agents
- Development of resveratrol, curcumin and anthocyanins.
- Determining optimal intervention schedules – investigation of dose-response relationships for dietary and pharmacological doses of chemopreventive agents.
- Development of long-term in vitro models for screening agents.
- Application and evaluation of human stem cells as novel in vitro/in vivo approaches for assessing efficacy of chemopreventive agents.
- Combining dietary chemopreventive agents with chemotherapeutic regimens for the treatment of cancer.
Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy
- Development of novel, sensitive and specific techniques for biomarker analysis (particularly LC-MS/MS and accelerator mass spectrometry based methods).
- Assessment of DNA damage (global and specific lesions) as a biomarker of efficacy for chemopreventive agents and chemotherapeutic drugs in humans.
- Determining the mechanisms of tamoxifen carcinogenesis in women and the role of tamoxifen DNA adduct formation in human tissues.
- Assessing the biological significance of DNA damage induced by occupational/environmental exposure to the carcinogen ethylene oxide.
- Development of novel, biomarker driven strategies towards personalized treatment of Chronic Lymphocytic Leukaemia.
To view Professor Brown's publications, please use the link below: